Drug profile · INN
sumatriptan
APO-SUMATRIPTAN
sumatriptan (APO-SUMATRIPTAN) is a serotonin 1b (5-ht1b) receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — sumatriptan
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 4
- Data quality
- 0.89
Quick answer
sumatriptan (APO-SUMATRIPTAN) is a serotonin 1b (5-ht1b) receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 1b (5-HT1b) receptor agonist
Primary target: 5-hydroxytryptamine receptor 1B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is sumatriptan?
sumatriptan (APO-SUMATRIPTAN) is a serotonin 1b (5-ht1b) receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sumatriptan?
APO-SUMATRIPTAN is a marketed brand name for sumatriptan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sumatriptan?
sumatriptan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.